Older adults · Connecticut
Studies for adults 50 and older in Connecticut
These studies set a minimum age of 50 or older in their official record. Many look at conditions more common with age, and some vaccine and memory studies specifically need older participants.
29 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersEarly Phase 1
Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
MODAG GmbH
- Location
- New Haven, CT
- Eligibility basics
- Ages 50–80
- RecruitingHealthy volunteersPhase 1/Phase 2
SV2A in Older Adults
Yale University
- Location
- New Haven, CT
- Eligibility basics
- Ages 50+
- RecruitingHealthy volunteersEarly Phase 1
PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults
Yale University
- Location
- West Haven, CT
- Eligibility basics
- Ages 65+
- RecruitingHealthy volunteersPhase 3
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
GlaxoSmithKline
- Location
- Stamford, CT + 130 other US sites
- Eligibility basics
- Ages 65+
- RecruitingPhase 2
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Merck Sharp & Dohme LLC
- Location
- New Haven, CT + 34 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- New Haven, CT + 67 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Farmington, CT + 56 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Amgen
- Location
- Waterford, CT + 54 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals
- Location
- Manchester, CT + 144 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Eli Lilly and Company
- Location
- Stamford, CT + 29 other US sites
- Eligibility basics
- Ages 55–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- New Haven, CT + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Adverum Biotechnologies, Inc.
- Location
- Waterford, CT + 78 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Farmington, CT + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
ONL Therapeutics
- Location
- Waterford, CT + 55 other US sites
- Eligibility basics
- Ages 55+
- Recruiting
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
i-Lumen Scientific AUS PTY LTD
- Location
- Manchester, CT + 5 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Amgen
- Location
- Greenwich, CT + 193 other US sites
- Eligibility basics
- Ages 50–105
- RecruitingPhase 2/Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
EyeBiotech Ltd.
- Location
- Danbury, CT + 51 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Anthos Therapeutics, Inc.
- Location
- Stamford, CT + 131 other US sites
- Eligibility basics
- Ages 65+
- RecruitingPhase 3
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or…
Ocular Therapeutix, Inc.
- Location
- Waterford, CT + 7 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in…
Apellis Pharmaceuticals, Inc.
- Location
- Danbury, CT + 77 other US sites
- Eligibility basics
- Ages 60+
- Recruiting
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
Edwards Lifesciences
- Location
- New Haven, CT + 49 other US sites
- Eligibility basics
- Ages 65+
- RecruitingPhase 1
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
Caregen Co. Ltd.
- Location
- Manchester, CT + 6 other US sites
- Eligibility basics
- Ages 50+
- RecruitingHealthy volunteers
Targeting Aging With a Ketone Ester for Function in Frailty
Buck Institute for Research on Aging
- Location
- Farmington, CT + 2 other US sites
- Eligibility basics
- Ages 65+
- RecruitingHealthy volunteersPhase 4
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Duke University
- Location
- New Haven, CT + 88 other US sites
- Eligibility basics
- Ages 75+